A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in Adults

Sixty subjects will be sequentially enrolled into one of five study groups (i.e., Group 1, Group 2, Group 3, Group 4, or Group 5) with 10 subjects per group in Groups 1-4 and 20 subjects in Group 5. Within each study group, subjects will be randomized to a treatment assignment of either AERAS-404 or placebo control at a ratio of 4:1 (Groups 1-4) or two different dose amounts of AERAS-404 or placebo control at a ratio of 9:9:2 (Group 5) administered by intramuscular injection on Study Day 0 and Study Day 56. The principal investigator will determine an appropriate interval between the vaccinations such that the entire group is not dosed at the same time. All subjects will receive the same treatment on Study Day 0 as they receive on Study Day 56. All subjects will be followed for safety and immunogenicity evaluations for 182 days. A total of eleven clinic visits are planned (excluding screening) for all subjects

Inclusion criteria

• Has completed written informed consent
• Is male or female
• Is age 18 through 45 years on Study Day 0
• Had BCG vaccination at least 5 years ago, documented through medical history or presence of scar
• Has general good health, confirmed by medical history and physical examination
• Has a Body Mass Index (BMI) between 19 and 33
• Agrees to complete a follow-up period of 182 days as required by the protocol
• Females: Agrees to avoid pregnancy from 28 days prior to Study Day 0 through the follow-up period of 182 days. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses) must agree to avoid pregnancy using an acceptable method
• Agrees to avoid elective surgery for the duration of the study
• Agrees to stay in contact with the investigative site for the study duration
• Completed simultaneous enrollment in Aeras Vaccine Development Registry protocol

Exclusion criteria

• Acute illness on Study Day 0
• Axillary temperature >=37.5 degrees Celsius on Study Day 0
• Evidence of significant active infection
• Used immunosuppressive medication within 42 days before Study Day 0
• Received immunoglobulin or blood products within 42 days before Study Day 0
• Received any investigational drug therapy or investigational vaccine within 182 days before Study Day 0
• Received inactivated influenza vaccine or inactivated tick-borne encephalitis vaccine within 14 days before entry into the study, or any other standard vaccine within 42 days before Study Day 0
• Current chronic drug therapy including hormone replacement such as thyroxin, insulin
• History or laboratory evidence of past, present or future possible immunodeficiency state which include any laboratory indication of HIV infection
• History of allergic disease or reactions, including eczema
• Previous medical history that may compromise safety of the subject in the study
• Evidence of new acute illness that may compromise the safety of subject in the study
• Evidence of chronic hepatitis
• Inability to discontinue daily medications except contraceptives during study period
• History of alcohol or drug abuse within past 2 years
• Tobacco or cannabis smoking three or more days per week
• Positive urine test for illicit drugs
• History or evidence of any systemic disease on physical examination
• History or evidence of active tuberculosis
• Shared a residence within the last year with a individual on anti-tuberculosis treatment or with culture or smear positive tuberculosis
• All females: Positive urine pregnancy test during screening
• Abnormal (per local laboratory parameters) chemistry and hematology parameters
• QuantiFERON®-TB Gold evidence of Mtb infection
• Received a tuberculin skin test within 3 months (90 days) prior to Study Day 0